On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas. The news coincided with the American Association for Cancer Research (AACR) Annual Meeting 2021, where Celularity delivered an oral presentation and two posters. Each showcased the viability of that therapeutic compound, CYNK-001, as a treatment for multiple, disparate indications.
March 23, 2021
Read Celularity's published study regarding CBLB ablation with CRISPR/Cas9 and if it enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
LifebankUSA, powered by Celularity Inc, and the world’s most comprehensive company for cord, placenta and tissue banking, today unveils a brand new website and announces a relocation to new headquarters in Florham Park, NJ,
April 2, 2020
Therapeutics startup Celularity announced Thursday morning that it has received FDA clearance to begin a clinical trial of a proposed stem-cell treatment for COVID-19. The approval of the New Jersey-based company’s IND application enables the company to begin a clinical trial with patients who have the disease.
April 2, 2020
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19.
Dr. Robert Hariri, CEO and founder of Celularity, discusses how the company is exploring a new treatment for COVID-19 as the pandemic intensifies.
The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer.
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of COVID-19 disease.